Compare Becton Dickinson and Co (BDX) vs Chevron Corp (CVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Chevron Corp — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Chevron Corp trades at $181.79 (market cap $361.99B). The key difference: Chevron Corp is far larger — about 8.7× Becton Dickinson and Co's market cap, and Chevron Corp pays the higher dividend (3.92%). Which is the better fit depends on your goals.
| BDX | CVX | |
|---|---|---|
Market Cap | $41.51B | $361.99B |
Sector | Health | Energy |
52-Week High | $185.39 | $211.14 |
52-Week Low | $135.49 | $146.72 |
Enterprise Value | $57.97B | $402.09B |
Dividend Yield | 2.79% | 3.92% |
Volume | — | 9,807,834 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
CVX trades at $181.77, up 3.04% today, with a bullish technical signal and strong analyst consensus. Recent earnings have consistently beaten estimates, though revenue and net income have declined year-over-year. The company maintains solid cash flow from operations and recently announced a $13.8 billion investment in Argentina's Vaca Muerta shale play, signaling growth commitment. High oil prices and geopolitical tensions are key near-term catalysts.
Outlook remains positive given Wall Street's $207.56 price target and 62% buy ratings, but risks include declining profit margins, volatile oil prices, and execution challenges on new projects. The stock offers value through dividends and strategic expansion, yet investors face headwinds from macroeconomic uncertainty and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
